What hepatology clinicians and their patients with alcohol-related liver disease think of wearable alcohol biosensors to aid abstinence from alcohol: A qualitative study.
Andrea DiMartini, Jaideep Behari, Jon Punzi, Michael Dunn, Ramon A Bataller, John M Jakicic, Mary McNulty, Ryan C Young, Mary Amanda Dew
{"title":"What hepatology clinicians and their patients with alcohol-related liver disease think of wearable alcohol biosensors to aid abstinence from alcohol: A qualitative study.","authors":"Andrea DiMartini, Jaideep Behari, Jon Punzi, Michael Dunn, Ramon A Bataller, John M Jakicic, Mary McNulty, Ryan C Young, Mary Amanda Dew","doi":"10.1111/dar.13978","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to determine acceptability and feasibility of innovative wearable alcohol biosensor monitors (ABM) for patients with alcohol-related liver disease (ALD) and their clinicians.</p><p><strong>Methods: </strong>Patients and clinicians at a tertiary care centre participated in qualitative interviews on usability, acceptability, feasibility, efficiency/effectiveness, impact of device on behaviour/clinical practice and preferences/barriers. Interviews were audiotaped, transcribed and coded using a constant comparison method for category themes.</p><p><strong>Results: </strong>Patients (n = 23) were 56% female, mean 44 years old, 87% White, with moderate-severe liver disease. Some felt the ABMs appearance was unappealing; others felt it provided an opportunity for openness and education of others. While some found it feasible to wear, others felt it was unrealistic to wear 24/7. Importantly, there were many positive themes on effectiveness/efficiency-participants felt the ABM could better record their alcohol use and patterns of use than they could remember. Patients felt wearing the ABM motivated abstinence, gave accountability and was a source of security. Clinicians (n = 13) were mostly hepatologists (77%), seeing on average 38 ALD patients/month. Clinicians felt seeing patterns and amounts of alcohol use could inform clinical decision making and treatments but expressed concern over the volume and complexity of data.</p><p><strong>Discussion and conclusions: </strong>Perspectives on ABMs for managing ALD were mixed among patients and providers. Future device designs may overcome acceptability barriers due to device appearance. However, for clinicians, the logistics of data gathering plus the complexity and volume of data produced by the ABM device requires considerable thought to make this an efficient tool for clinical use.</p><p><strong>Clinicaltrials: </strong>gov identifier NCT03533660: Alcohol biosensor monitoring for alcohol liver disease.</p>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dar.13978","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: We aimed to determine acceptability and feasibility of innovative wearable alcohol biosensor monitors (ABM) for patients with alcohol-related liver disease (ALD) and their clinicians.
Methods: Patients and clinicians at a tertiary care centre participated in qualitative interviews on usability, acceptability, feasibility, efficiency/effectiveness, impact of device on behaviour/clinical practice and preferences/barriers. Interviews were audiotaped, transcribed and coded using a constant comparison method for category themes.
Results: Patients (n = 23) were 56% female, mean 44 years old, 87% White, with moderate-severe liver disease. Some felt the ABMs appearance was unappealing; others felt it provided an opportunity for openness and education of others. While some found it feasible to wear, others felt it was unrealistic to wear 24/7. Importantly, there were many positive themes on effectiveness/efficiency-participants felt the ABM could better record their alcohol use and patterns of use than they could remember. Patients felt wearing the ABM motivated abstinence, gave accountability and was a source of security. Clinicians (n = 13) were mostly hepatologists (77%), seeing on average 38 ALD patients/month. Clinicians felt seeing patterns and amounts of alcohol use could inform clinical decision making and treatments but expressed concern over the volume and complexity of data.
Discussion and conclusions: Perspectives on ABMs for managing ALD were mixed among patients and providers. Future device designs may overcome acceptability barriers due to device appearance. However, for clinicians, the logistics of data gathering plus the complexity and volume of data produced by the ABM device requires considerable thought to make this an efficient tool for clinical use.
期刊介绍：
Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
